[1] Baekkevold ES,Roussigné M,Yamanaka T,et al.Molecular Characterization of NF-HEV,a Nuclear FactorPreferentially Expressed in Human High EndothelialVenules[J].Am J Pathol，2003，163（1）：69-79.
[2] Jochen Schmitz,Alexander Owyang,Elizabeth Oldham,etal.IL-33,an Interleukin-1-Like Cytokine that Signalsvia the IL-1 Receptor-Related Protein ST2 and InducesT Helper Type 2-Associated Cytokines[J].Immunity，2005，23（5）：479-490.
[3] Drake Li Yin，Kita Hirohito.IL-33:Biological Properties,Functions,and Roles in Airway Disease[J].ImmunologicalReviews，2017，278（1）：173-184.
[4] Liew FY,Girard JP,Turnquist HR.Interleukin-33 in Healthand Disease[J].Nat Rev Immunol，2016，16：676-689.
[5] Takenaga Keizo,Akimoto Miho,Koshikawa Nobuko,et al.Cancer Cell-Derived Interleukin-33 Decoy Receptor sST2Enhances Orthotopic Tumor Growth in a Murine PancreaticCancer Model[J].PloS One，2020，15（4）：e0232230.
[6] Kakkar Rahul，Lee Richard T.The IL-33/ST2 Pathway:Therapeutic Target and Novel Biomarker[J].NatureReviews.Drug Discovery，2008（10）：827-840.
[7] Tominaga Shin-ichi.A Putative Protein of a Growth SpecificcDNA from BALB/C-3T3 Cells Is Highly Similar to theExtracellular Portion of Mouse Interleukin 1 Receptor[J].FEBS Letters，1989，258（2）：301-304.
[8] Kriechbaum Steffen D,Wiedenroth Christoph B,PetersKarina,et al.Galectin-3,GDF-15,and sST2 for theAssessment of Disease Severity and Therapy Response inPatients Suffering from Inoperable Chronic ThromboembolicPulmonary Hypertension[J].Biomarkers：BiochemicalIndicators of Exposure,Response,and Susceptibility toChemicals，2020，25（7）：578-586.
[9] McLaren James E,Michael Daryn R,Salter Rebecca C,etal.IL-33 Reduces Macrophage Foam Cell Formation[J].Journal of Immunology，2010，185（2）：1222-1229.
[10] 王耀坤，陈颖，聂姗姗，等.IL-33/ST2轴在急性脑梗死大鼠炎性损伤中的作用[J].黑龙江医药科学，2021，44（6）：1-4.
[11] 李秋月，白春林，丘美玲.可溶性基质裂解素2与心肌纤维化相关性的研究进展[J].中西医结合心脑血管病杂志，2022，20（22）：4123-4126.
[12] Bergers G,Reikerstorfer A,Braselmann S,et al.AlternativePromoter Usage of the Fos-Responsive Gene Fit-1Generates mRNA Isoforms Coding for either Secreted orMembrane-Bound Proteins Related to the IL-1 Receptor[J].The EMBO Journal，1994，13（5）：1176-1188.
[13] Kumar S,Tzimas MN,Griswold DE,et al.Expression ofST2,an Interleukin-1 Receptor Homologue,Is Induced byProinflammatory Stimuli[J].Biochemical and BiophysicalResearch Communications，1997，235（3）：474-478.
[14] Svitlana Demyanets,Christoph Kaun,Richard Pentz,etal.Components of the Interleukin-33/ST2 System AreDifferentially Expressed and Regulated in Human CardiacCells and in Cells of the Cardiac Vasculature[J].Journal ofMolecular and Cellular Cardiology，2013，60：16-26.
[15] Cindy Barnig,Nelly Frossard,Bruce D Levy.TowardsTargeting Resolution Pathways of Airway Inflammation inAsthma[J].Pharmacology & Therapeutics，2018，186：98-113.
[16] Magat Jenna M,Thomas Joanna L,Dumouchel Justin P,etal.Endogenous IL-33 and Its Autoamplification of IL-33/ST2 Pathway Play an Important Role in Asthma[J].Journalof Immunology，2020，204（6）：1592-1597.
[17] Gudbjartsson DF,Bjornsdottir US,Halapi E,et al.SequenceVariants Affecting Eosinophil Numbers Associate withAsthma and Myocardial Infarction[J].Nat Genet，2009，41（3）：342-347.
[18] Maria E Ketelaar,Michael A Portelli,F Nicole Dijk,et al.Phenotypic and Functional Translation of IL-33Genetics in Asthma[J].The Journal of Allergy and ClinicalImmunology，2020，147（1）：144-157.
[19] B?nnelykke Klaus,Sleiman Patrick,Nielsen Kasper,et al.A Genome-Wide Association Study Identifies CDHR3 asa Susceptibility Locus for Early Childhood Asthma withSevere Exacerbations[J].Nature Genetics，2014，46（1）：51-55.
[20] Drake LY,Kita H.IL-33:Biological Properties,Functions,and Roles in Airway Disease[J].Immunol Rev，2017，278（1）：173-184.
[21] Hamzaoui A,Berraies A,Kaabachi W,et al.InducedSputum Levels of IL-33 and Soluble ST2 in YoungAsthmatic Children[J].Asthma，2013，50（8）：803-809.
[22] Byers Derek E,Alexander-Brett Jennifer,Patel Anand C,et al.Long-Term IL-33-Producing Epithelial ProgenitorCells in Chronic Obstructive Lung Disease[J].The Journalof Clinical Investigation，2013，123（9）：3967-3982.
[23] Kearley J,Silver JS,Sanden C,et al.Cigarette SmokeSilences Innate Lymphoid Cell Function and Facilitates anExacerbated Type I Lnterleukin-33-Dependent Responseto Infection[J].Immunity，2015，42（3）：566-579.
[24] Rabe Klaus F,Celli Bartolome R,Wechsler Michael E,et al.Safety and Efficacy of Itepekimab in Patients withModerate-to-Severe COPD:A Genetic Association Studyand Randomised,Double-Blind,Phase 2a Trial[J].TheLancet Respiratory Medicine，2021，9（11）：1288-1298.
[25] Jeanne Allinne,George Scott,Wei Keat Lim,et al.IL-33Blockade Affects Mediators of Persistence and Exacerbationin a Model of Chronic Airway Inflammation[J].The Journalof Allergy and Clinical Immunology，2019，144（6）：1624-1637.
[26] Gluck J,Rymarczyk B,Rogala B.Serum IL-33 but not ST2Level Is Elevated in Intermittent Allergic Rhinitis and Is aMarker of the Disease Severity[J].Inflamm Res，2012，61（6）：547-550.
[27] Kim JH,Yoon MG,Seo DH,et al.Detection of AllergenSpecific Antibodies from Nasal Secretion of AllergicRhinitis Patients[J].Allergy Asthma Immunol Res，2016，8（4）：329-337.
[28] 樊华，覃泰杰，叶林松，等.接受免疫治疗的变应性鼻炎儿童患者外周血中IL-25、IL-33的表达和EOS计数及意义[J].临床耳鼻咽喉头颈外科杂志，2018，32（6）：443-446.
[29] 彭海森，朱新华.IL-33/ST2信号通路在变应性鼻炎发病机制中的研究进展[J].临床耳鼻咽喉头颈外科杂志，2019，33（10）：910-914.
[30] Lott JM,Sumpter TL,Turnquist HR.New Dog and NewTricks:Evolving Roles for IL-33 in Type 2 Immunity[J].JLeukoc Biol，2015，97：1037-1048.
[31] Akimoto M,Maruyama R,Takamaru H,et al.Soluble IL 33 Receptor sST2 Inhibits Colorectal Cancer MalignantGrowth by Modifying the Tumour Microenvironment[J].NatCommun，2016，7：13589.
[32] Jovanovic Ivan P,Pejnovic Nada N,Radosavljevic GordanaD,et al.IL-33/ST2 Axis in Innate and Acquired Immunityto Tumors[J].Oncoimmunology，2012，1（2）：229-231.
[33] Kotsiou OS,Jagirdar RM,Papazoglou ED,et al.PleuralEffusion IL-33/sST2 Levels and Effects of Low and HighIL-33/sST2 Levels on Human Mesothelial Cell Adhesionand Migration[J].Inflammation，2019，42（6）：2072-2085.
[34] Wang Kailing,Shan Shan,Yang Zongjun,et al.IL-33Blockade Suppresses Tumor Growth of Human Lung Cancerthrough Direct and Indirect Pathways in a PreclinicalModel[J].Oncotarget，2017（40）：68571-68582.
[35] Afferni Claudia,Buccione Carla,Andreone Sara,et al.The Pleiotropic Immunomodulatory Functions of IL-33and Its Implications in Tumor Immunity[J].Frontiers inImmunology，2018，9：2601.
[36] Landskron Glauben,De la Fuente López Marjorie,Dubois-Camacho Karen,et al.Interleukin 33/ST2 Axis ComponentsAre Associated to Desmoplasia,a Metastasis-RelatedFactor in Colorectal Cancer[J].Frontiers in Immunology，2019，10：1394.
[37] Fang Yujiang,Zhao Lei,Xiao Huaping,et al.IL-33 Actsas a Foe to MIA PaCa-2 Pancreatic Cancer[J].MedicalOncology(Northwood,London,England)，2017，34（2）：23.
[38] Shi X,Tang Y,Sun X,et al.Interleukin-33-InducedImmune Tolerance Is Associated with the Imbalance ofMemory and Naive T-Lymphocyte Subsets[J].Mol MedRep，2016，14（5）：4837-4843.
[39] Gao S,Huan SL,Han LY,et al.Over Expression of SerumsST2 Is Associated with Poor Prognosis in Acuteon-Chronic Hepatitis B Liver Failure[J].Clin Res HepatolGastroenterol，2015，39（3）：315-323.
[40] Gao X,Chi X,Wang X.IL-33 Clear Hepatitis B Virus inHydrodynamic HBV Mouse Model through ST2 Expressedon NK Cell[J].Journal of Hepatology，2016，64（2）：S604-S605.
[41] Christi A Matteoni,Zobair M Younossi,Terry Gramlich,et al.Nonalcoholic Fatty Liver Disease:A Spectrum ofClinical and Pathological Severity[J].Gastroenterology，1999，116（6）：1413-1419.
[42] Miller Ashley M,Asquith Darren L,Hueber Axel J,et al.Interleukin-33 Induces Protective Effects in AdiposeTissue Inflammation during Obesity in Mice[J].CirculationResearch，2010，10（5）：650-658.
[43] Julia S,Anja F,Angeliki D,et al.IL-33 Receptor-Expressing Regulatory T Cells Are Highly Activated,Th2Biased and Suppress CD4+T Cell Proliferation through IL-10 and TGFβ Release[J].PLoS One，2016，11（8）：e0161507.
[44] MacDonald KG,Dawson NA,Huang Q,et al.Regulatory TCells Produce Profibrotic Cytokines in the Skin of Patientswith Systemics Clerosis[J].Allergy Clin Immunol，2015，135（4）：946-955.
[45] Weiskirchen R,Meurer SK,Liedtke C,et al.Mast Cells inLiver Fibrogenesis[J].Cells，2019，8（1）：1429.
[46] Antunes MM，Araujo AM，Diniz AB,et al.IL-33Signalling in Liver Immune Cells Enhances Drug-InducedLiver Injury and Inflammation[J].Inflamm Res，2018，67（1）：77-88.
[47] 黄伊，欧阳泽玥，马龙，等.IL-33/ST2信号通路在肝脏炎症中的免疫调节作用[J].当代医学，2020，26（36）：1-4.
[48] 中国心血管健康与疾病报告2020概要[J].中国循环杂志，2021，36（6）：521-545.
[49] 吕海珍，吕云，周荣，等.血清HCY、sST2和NTproBNP联合检测对慢性心力衰竭诊断及心功能评价的价值[J].中国实验诊断学，2019，23（6）：1002-1006.
[50] Pascual-Figal Domingo A,Lax Antonio,Perez-MartinezMaria Teresa,et al.Clinical Relevance of sST2 in CardiacDiseases[J].Clinical Chemistry and Laboratory Medicine，2016，54（1）：29-35.
[51] Lara Matilla,Vanessa Arrieta,Eva Jover,et al.SolubleSt2 Induces Cardiac Fibroblast Activation and CollagenSynthesis via Neuropilin-1[J].Cells，2020，9（7）：1667.
[52] Marco Ciccone,Francesca Cortese,Michele Gesualdo,et al.A Novel Cardiac Bio-Marker:ST2:A Review[J].Molecules，2013，18（12）：15314-15328.
[53] Josep Lupón,Sandra Sanders-van Wijk,James L Januzzi,et al.Prediction of Survival and Magnitude of ReverseRemodeling Using the ST2-R2 Score in Heart Failure:AMulticenter Study[J].International Journal of Cardiology，2016，204：242-247.
[54] Yin Xiaoyun,Cao Huajun,Wei Yingjie,et al.Alteration ofthe IL-33-sST2 Pathway in Hypertensive Patients and aMouse Model[J].Hypertension Research:Official Journal ofthe Japanese Society of Hypertension，2019，42（11）：1664-1671.
[55] Dimitropoulos Stathis,Mystakidi Vasiliki Chara,OikonomouEvangelos,et al.Association of Soluble Suppression ofTumorigenesis-2(ST2)with Endothelial Function inPatients with Ischemic Heart Failure[J].InternationalJournal of Molecular Sciences，2020，21（24）：9385.
[56] 张文婧，郭文玲.IL-33/ST2通路在心血管疾病中作用及机制的研究进展[J].中西医结合心脑血管病杂志，2022，20（20）：3724-3726.
[57] Wechsler Michael E,Ruddy Marcella K,Pavord Ian D,et al.Efficacy and Safety of Itepekimab in Patients withModerate-to-Severe Asthma[J].New England Journal ofMedicine，2021，38（18）：1656-1668.
[58] Elizabeth England,D Gareth Rees,Lan Christopher Scott,etal.Tozorakimab(MEDI3506):A Dual-Pharmacology Anti-IL-33 Antibody that Inhibits IL-33 Signalling Via ST2and RAGE/EGFR to Reduce Inflammation and EpithelialDysfunction[J].BioRxiv，2023，13（1）：9825.
[59] Okragly AJ,Corwin KB,Elia M,et al.Generation andCharacterization of Torudokimab(LY3375880):AMonoclonal Antibody that Neutralizes Interleukin-33[J].Inflamm Res，2021，14：3823-3835.
[60] Chen YL,Gutowska-Owsiak D,Hardman CS,et al.Proofof-Concept Clinical Trial of Etokimab Shows a Key Rolefor IL-33 in Atopic Dermatitis Pathogenesis[J].Sci TranslMed，2019，11（515）：eaax2945.
[61] Scott I,Killick H,Newcombe P,et al.Proof of Mechanismfor Anti-Interleukin-33 Antibody Tozorakimab in a Phase1 Study in Healthy Adults and Patients with ChronicObstructive Pulmonary Disease[J].American Journal ofRespiratory and Critical Care Medicine，2022，205：A2397.
[62] 刘素阁，齐亚娟，王淑锦，等.阿托伐他汀对慢性心力衰竭患者血浆细胞因子水平的影响[J].中国慢性病预防与控制，2018，26（8）：610-613.
[63] 王文静，王晓玥，王雅坤.心通口服液联合瑞舒伐他汀对射血分数保留心力衰竭病人血清可溶性ST2和白细胞介素-33水平的影响[J].中西医结合心脑血管病杂志，2022，20（8）：1457-1460.
